Hot Features
Premium
Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0.00 |
|
|||||
| News | - |
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Acerus Pharmaceuticals Corporation (QB) | ASPCF | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.21988 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.21988 | 0.21988 |
| Trades | Shares Traded | Average Volume |
|---|---|---|
| 0 | 0.00 | - |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.21988 | USD |
Acerus Pharmaceuticals Corporation (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 1.69M | 7.71M | 662.94k | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Acerus Pharmaceuticals (QB) News
Real-Time news about Acerus Pharmaceuticals Corporation (QB) (OTCMarkets): 0 recent articles
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ASPCF Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
Acerus Pharmaceuticals (QB) Description
| Acerus is a Canadian pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience. Founded in 2008, Acerus has quickly grown into a fully integrated company with expertise in all stages of the pharmaceutical product lifecycle, and focus in the therapeutic areas of Men's Health (Urology) and Women's Health (Hormone Replacement Therapy). Acerus has global rights to NATESTO, a product utilizing our licensed nasal gel technology, is the first and only testosterone nasal gel approved in Canada, and the United States for replacement therapy in adult males diagnosed with hypogonadism. Acerus operates from a Mississauga-based office, and is listed on the Toronto Stock Exchange (TSX:ASP) |
